Chu, Min Kyung
Kim, Byung-Su
Chung, Pil-Wook
Kim, Byung-Kun
Lee, Mi Ji
Park, Jeong Wook
Ahn, Jin-Young
Bae, Dae Woong
Song, Tae-Jin
Sohn, Jong-Hee
Oh, Kyungmi
Kim, Daeyoung
Kim, Jae-Moon
Kim, Soo-Kyoung
Choi, Yun-Ju
Chung, Jae Myun
Moon, Heui-Soo
Chung, Chin-Sang
Park, Kwang-Yeol
Cho, Soo-Jin
Funding for this research was provided by:
Yonsei University College of Medicine (2018-32-0037, 2018-32-0037)
National Research Foundation of Korea 2 (2019R1F1A1053841)
Korean Neurological Association (16-MI-09)
Article History
Received: 20 December 2020
Accepted: 15 March 2021
First Online: 25 March 2021
Competing interests
: Drs. BS Kim, PW Chung, BK Kim, MJ Lee, JW Park, JY Ahn, DW Bae, TJ Song, JH Sohn, K Oh, D Kim, JM Kim, SK Kim, YJ Choi, JM Chung, HS Moon, CS Chung, and KY Park declare that they have no competing interests. Dr. SJ Cho was involved as a site investigator of a multicentre trial sponsored by Otsuka Korea, Eli Lilly and Co. and Novartis; functioned as an advisory member for Teva; and received research support from the Hallym University Research Fund 2016 and a grant from the Korean Neurological Association (KNA-16-MI-09). Dr. MK Chu was a site investigator for a multicentre trial sponsored by Otsuka Korea, Novartis, International AG, and Eli Lilly and Co. He functioned as an advisory member for Teva and received lecture honoraria from Allergan Korea, Handok-Teva, and Yuyu Pharmaceutical Company over the past 24 months. He received grants from the Yonsei University College of Medicine (2018-32-0037) and National Research Foundation of Korea (2019R1F1A1053841).